News | November 07, 2024
JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
We now rank 3rd in pharmaceutical production by volume and 14th by value
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Cetirizine is used for relief of symptoms of hay fever and other allergic conditions
Subscribe To Our Newsletter & Stay Updated
